Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13087065 | 0.98 | PIK3C3 (0.39) | CCR2PIK3C3P2RX3MCL1IGF1R | |
| SCHEMBL13087186 | 0.91 | PIK3C3 (0.40) | CCR2PIK3C3P2RX3IGF1RCDK9 | |
| SCHEMBL13087049 | 0.89 | MKNK2 (0.41) | CCR2PIK3C3P2RX3IGF1RCDK9 | |
| SCHEMBL13087137 | 0.89 | PIK3C3 (0.42) | CCR2PIK3C3P2RX3IGF1RCDK9 | |
| SCHEMBL14706307 | 0.87 | PIK3C3 (0.42) | CCR2PIK3C3P2RX3IGF1RCDK9 | |
| SCHEMBL13087222 | 0.86 | MCL1 (0.36) | CCR2PIK3C3MCL1PPARG | |
| SCHEMBL13087154 | 0.84 | PIK3C3 (0.37) | CCR2PIK3C3MCL1PPARG | |
| SCHEMBL830571 | 0.74 | CCR2 (0.40) | CCR2PIK3C3P2RX3MCL1IGF1R | |
| SCHEMBL831472 | 0.73 | CCR2 (0.44) | CCR2P2RX3MCL1IGF1RCDK9 | |
| SCHEMBL13087152 | 0.72 | MEN1 (0.38) | CCR2PIK3C3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100260711-A1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260711-A1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260711-A1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, INMT, IDO2 | CCR2 1374/4885PIK3C3 1300/4885P2RX3 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.